AIMI - Medical Information for Tagrisso® (osimertinib) | AstraZeneca Oncology

Medical Information on Tagrisso® (osimertinib) Available via AIMI

AstraZeneca's Medical Virtual Assistant, AIMI, provides healthcare professionals with timely, accurate, and non-promotional medical information. If you have questions about TAGRISSO, AIMI is available to support your clinical decision-making needs.

How to Access Medical Information on TAGRISSO

Start a conversation with AIMI to receive tailored medical information about TAGRISSO. AIMI is available 24/7 and supports scientific, evidence-based inquiries from healthcare professionals.

Chat with AIMI

How AIMI Can Help

 
  • What are the approved indications for TAGRISSO
  • Are there biomarker requirements for TAGRISSO therapy?
  • Is TAGRISSO approved for elderly patients?
  • Is TAGRISSO approved for children?
  • What is TAGRISSO's storage stability?
  • What is pharmacokinetics profile of TAGRISSO?
  • What is the mechanism of action of TAGRISSO?
  • How can I enroll my patient in any TAGRISSO's trial?
  • I would like to discuss TAGRISSO with an MSL
  
 
AIMI can provide detailed, evidence-based answers to these and other questions to healthcare professionals.

This information is intended to be a concise summation of representative clinical trial data, rather than being all-inclusive; therefore, all available published literature may not be incorporated into this response.

Provided by AstraZeneca Pharmaceuticals LP ©AstraZeneca 2026